Cellectis S.A. CLLS was a big mover last session, as the company saw its shares rise 17% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company —as the stock is now up 21.8% in the past one-month time frame.
The upmove could have been driven by Gilead Sciences’ acquisition of Kite Pharma, which marks a large investment by Gilead into a cancer treatment called chimeric antigen receptor T-cell therapy, or CAR-T. Cellectis is presently working in CAR-T therapy.
The company has seen one positive estimate revision in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks, suggesting that more solid trading could be ahead for Cellectis. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Cellectis currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
A better-ranked stock in the Medical – Biomedical and Genetics industry is Akari Therapeutics PLC AKTX, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is CLLS going up? Or down? Predict to see what others think: Up or Down
Zacks' 10-Minute Stock-Picking Secret
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.
But here's something even more remarkable: You can master this proven system without going to a single class or seminar. And then you can apply it to your portfolio in as little as 10 minutes a month.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment